CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock

Key Points

• CFO Christopher Ogden sold 19,323 shares on March 17 for $6.42 each, totaling $124,053.66 and reducing his stake by 6.11% to 296,948 shares (valued at about $1.91M).
• CytomX priced an underwritten equity offering of roughly $250M (about 45.99M shares at $5.30 plus pre‑funded warrants), which materially boosts cash runway but will dilute existing shareholders.
• The company reported a weak quarter — EPS of -$0.22 versus -$0.08 expected and revenue $0.66M vs $7.33M est. — yet several analysts raised price targets (e.g., Barclays to $16), and the stock traded up on heavy volume.

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CFO Christopher Ogden sold 19,323 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $124,053.66. Following the sale, the chief financial officer owned 296,948 shares of the company's stock, valued at $1,906,406.16. This trade represents a 6.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CytomX Therapeutics Stock Up 8.3%

NASDAQ:CTMX traded up $0.37 on Thursday, reaching $4.77. The stock had a trading volume of 13,412,791 shares, compared to its average volume of 6,618,611. The company has a market capitalization of $810.96 million, a P/E ratio of -119.13 and a beta of 2.44. CytomX Therapeutics, Inc. has a 1-year low of $0.40 and a 1-year high of $8.21. The stock has a fifty day moving average price of $5.27 and a 200-day moving average price of $4.10.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%.The firm had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. Sell-side analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several firms raised ratings and price targets (notably Barclays to $16/"Overweight", Guggenheim to $15/"Buy", Wedbush to $11), sending bullish signals about the company’s pipeline value and upside potential. Barclays/Tickerreport coverage
• Neutral Sentiment: CytomX priced a large underwritten equity offering to raise roughly $250M (45.99M shares at $5.30 and pre-funded warrants), which materially boosts cash runway to fund programs but also dilutes existing holders; the deal includes a 30‑day option for additional shares. Globe Newswire: Offering Pricing
• Neutral Sentiment: Additional media coverage and filings reflect the equity raise (reports cite $234M–$250M sizes and pricing at $5.30), confirming strong capital access but increasing share count. TipRanks: Equity Offering
• Neutral Sentiment: Reported short interest data appears negligible/erroneous (shows 0 shares), so short‑seller pressure is not a clear factor in today’s move. (No external article link available for the short interest snapshot.)
• Negative Sentiment: Recent quarterly results disappointed consensus (EPS and revenue misses reported), a headwind that analysts have noted and that could temper enthusiasm despite upgrades. Earnings Miss Article
• Negative Sentiment: HC Wainwright cut near‑term EPS forecasts substantially (larger FY2026/FY2027 losses now modeled), highlighting higher expected burn even with new capital — a negative for near‑term profitability metrics. HC Wainwright Estimates Summary
• Negative Sentiment: Independent commentary (Seeking Alpha) cautions that early clinical data may not justify elevated valuation levels, suggesting upside may be tied to significant trial progress rather than near‑term fundamentals. Seeking Alpha: Valuation Caution

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Orbimed Advisors LLC acquired a new position in CytomX Therapeutics during the 2nd quarter worth $19,208,000. Commodore Capital LP acquired a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at $17,462,000. Perceptive Advisors LLC bought a new stake in shares of CytomX Therapeutics during the second quarter worth $15,876,000. Franklin Resources Inc. bought a new stake in shares of CytomX Therapeutics during the second quarter worth $13,096,000. Finally, Vivo Capital LLC acquired a new position in shares of CytomX Therapeutics during the second quarter valued at $13,096,000. Institutional investors own 67.77% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on CTMX. HC Wainwright lifted their price objective on CytomX Therapeutics from $10.00 to $17.00 and gave the company a "buy" rating in a research report on Monday. Cantor Fitzgerald increased their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an "overweight" rating in a report on Wednesday, February 4th. Barclays raised their target price on CytomX Therapeutics from $10.00 to $16.00 and gave the company an "overweight" rating in a research note on Thursday. Oppenheimer reaffirmed an "outperform" rating and issued a $12.00 price target on shares of CytomX Therapeutics in a report on Monday. Finally, JPMorgan Chase & Co. upgraded shares of CytomX Therapeutics from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $7.00 to $12.00 in a research report on Monday. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $13.22.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX's pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.